Objective
The emergence of highly diverse resistance mechanisms among pathogens requires their detailed analysis to guarantee an efficient medical treatment. The gold standard in clinical diagnostics is based on the cultivation of bacteria and their phenotypical characterisation. However, these methods are labour-intensive and time-consuming lasting in some cases up to a few weeks. Thus, faster diagnostic techniques are necessary to ensure an immediate and targeted treatment of the patient. DNA-based diagnostics can provide the relevant results within a few hours.
The requirements for a clinical DNA-based characterisation method are high; more than 1000 clinically relevant antibiotic resistance genes, a few hundred phylogenetic marker genes and virulence factors have to be targeted (including SNP detection). The limit of detection has to be low because a few 100 bacterial cells in the blood system can lead to the death of the patient. It should be possible to analyse a wide range of clinical sample origins such as stool, blood, urine and saliva using the same test. In addition, the results have to be obtained within a single working day.
In our project, we will develop two diagnostic systems that can be with direct sample material from patients. Thus, the time-consuming cultivation of pathogens will be avoided. Additionally, the test will be more sensitive, specific and faster than any other test on the market using an innovative DNA probe concept.
Fields of science
- natural sciencesbiological sciencesgeneticsDNA
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
- natural sciencesbiological sciencesmolecular biology
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
69622 Villeurbanne Cedex
France
See on map
Participants (10)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75794 Paris
See on map
1210 Wien
See on map
CV4 8UW Coventry
See on map
10 000 Zagreb
See on map
6525 XZ Nijmegen
See on map
3500 Hasselt
See on map
69004 Lyon
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28359 Bremen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
LL55 2BD Caernarfon
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
69616 Villeurbanne
See on map